Ionamin

Caloric Restriction, Obesity, Type 2 Diabetes + 6 more
Treatment
3 FDA approvals
20 Active Studies for Ionamin

What is Ionamin

PhentermineThe Generic name of this drug
Treatment SummaryPhentermine is an anti-obesity drug that works by suppressing the appetite. It was introduced in 1959 and approved by the FDA for short-term weight management. Phentermine was originally offered as a combination drug with fenfluramine and dexfenfluramine, but this was discontinued due to reports of abnormal valves in 30% of consumers. In 2012, phentermine was approved for use alone or in combination with topiramate. It has a low risk of addiction and is classified as Schedule IV drug.
Ionaminis the brand name
image of different drug pills on a surface
Ionamin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ionamin
Phentermine
1959
298

Approved as Treatment by the FDA

Phentermine, also known as Ionamin, is approved by the FDA for 3 uses including Obesity and Comorbidity .
Obesity
Used to treat Obesity in combination with Topiramate
Comorbidity
Used to treat one related comorbidity in combination with Topiramate
Regime of weight reduction

Effectiveness

How Ionamin Affects PatientsPhentermine works by suppressing appetite, possibly due to an increase in leptin. It also may increase the amount of energy used when resting. In clinical studies, patients taking phentermine lost an average of 3.6 kg in 2-24 weeks compared to those taking a placebo. Additionally, these patients were able to keep their weight off even after stopping taking the drug. Phentermine is a derivative of the amphetamines, but does not cause any of the amphetamine-related side effects, such as stimulation of the central nervous system, increased blood pressure, or changes in heart rate.
How Ionamin works in the bodyPhentermine works by releasing a special chemical called noradrenaline in the brain. This chemical increases the activity of certain receptors, making them more sensitive to energy signals. It also suppresses the hunger signal by reducing the activity of another chemical called neuropeptide Y. Lastly, it has a weak effect on monoamine oxidase, which is a chemical in the brain responsible for breaking down certain chemicals. All of these effects work together to make us feel less hungry and more energized.

When to interrupt dosage

The indicated dosage of Ionamin relies upon the diagnosed circumstances, such as Regime of weight reduction, Hyperlipidemia and Type 2 Diabetes. The measure of dosage additionally fluctuates in accordance with the method of delivery (e.g. Oral or Tablet) featured in the table underneath.
Condition
Dosage
Administration
Obesity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Caloric Restriction
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Type 2 Diabetes
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Hypertensive disease
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
High Cholesterol
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Regime of weight reduction
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Chronic Weight Management therapy
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
increase in physical activity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Comorbidity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral

Warnings

Ionamin Contraindications
Condition
Risk Level
Notes
Hyperthyroidism
Do Not Combine
concomitant use or 14 days after discontinuation
Do Not Combine
Agitation
Do Not Combine
Drug abuse
Do Not Combine
Cardiovascular Diseases
Do Not Combine
Open-angle glaucoma
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Phentermine may interact with Pulse Frequency
There are 20 known major drug interactions with Ionamin.
Common Ionamin Drug Interactions
Drug Name
Risk Level
Description
Iobenguane
Major
Phentermine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylene blue
Major
Phentermine may increase the serotonergic activities of Methylene blue.
Mirtazapine
Major
Phentermine may increase the serotonergic activities of Mirtazapine.
1-benzylimidazole
Minor
The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Phentermine.
4-Methoxyamphetamine
Minor
The risk or severity of hypertension can be increased when Phentermine is combined with 4-Methoxyamphetamine.
Ionamin Toxicity & Overdose RiskThe highest dose of phentermine that has been found to be toxic in rats is 151 mg/kg. Signs of acute overdose can range from restlessness, tremors, and confusion to fatigue and depression. It can also affect the cardiovascular system, causing rapid heartbeat, abnormal heart rhythms, high or low blood pressure, or circulation collapse. There may also be gastrointestinal symptoms such as nausea, vomiting, diarrhea, or abdominal cramps. Treatment for overdose includes symptom relief, lavage, and sedation with barbiturates. Chronic overdosage may result in skin problems, insomnia, irritability, and changes in personality or behavior.

Ionamin Novel Uses: Which Conditions Have a Clinical Trial Featuring Ionamin?

104 active clinical trials are presently being conducted to assess the efficacy of Ionamin in providing a therapeutic management of Type 2 Diabetes, Weight Reduction Regimens and Diseases.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
96 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Obesity
0 Actively Recruiting
Hypertensive disease
0 Actively Recruiting
Comorbidity
0 Actively Recruiting
High Cholesterol
17 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Early Phase 1
Caloric Restriction
0 Actively Recruiting
Regime of weight reduction
0 Actively Recruiting
increase in physical activity
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting

Ionamin Reviews: What are patients saying about Ionamin?

5Patient Review
7/31/2013
Ionamin for Overweight
I've been taking this medication for a while now, and it's really great. I'm a bit heavier than I was in high school, but that's not necessarily a bad thing. My doctor monitors my bloodwork every six months and I haven't had any adverse effects.
5Patient Review
3/28/2010
Ionamin for Overweight
Phentermine has helped me lose 18 pounds in just three months, and I'm hoping to lose 20 more pounds with this round of treatment. I've also noticed that my sweating has increased when working out, which means that my body is burning fat more efficiently. This drug is really effective!
5Patient Review
1/12/2008
Ionamin for Overweight
3.7Patient Review
9/23/2010
Ionamin for Overweight
I had tried to lose weight through diet and exercise after my second baby, but saw no results. A doctor then prescribed this pill to me, and I dropped 30 pounds in three months. I have now been off the pill for five months and have not gained any weight back, which is amazing.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ionamin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Ionamin still on the market?

"Ionamin is no longer available in the United States. If the FDA has approved generic versions of this product, there may be generic equivalents available."

Answered by AI

What kind of drug is Ionamin?

"Ionamin is a stimulant that is used in combination with diet and exercise to treat obesity in people who have risk factors such as high blood pressure, high cholesterol, or diabetes."

Answered by AI

Is phentermine effective for weight loss?

"Phentermine is effective for weight loss, with people typically losing 3% of their initial body weight after 3 months and 5-7% after 6 months. Some people report even more weight loss than this."

Answered by AI

Do you need a prescription for Ionamin?

"Ionamin is a prescription medicine used to treat obesity. It may be used alone or with other medications. Ionamin belongs to a class of drugs called CNS Stimulants, which includes Anorexiants and Stimulants. Sympathomimetic drugs act on the sympathetic nervous system."

Answered by AI

Clinical Trials for Ionamin

Image of Lipid Clinic at Brown University Health in Providence, United States.

2-HOBA Supplementation for High Cholesterol

18 - 69
All Sexes
Providence, RI
The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels. The main questions it aims to answer are: Does 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood? Participants will: Take 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers
Waitlist Available
Has No Placebo
Lipid Clinic at Brown University HealthWenliang Song, MD
Have you considered Ionamin clinical trials? We made a collection of clinical trials featuring Ionamin, we think they might fit your search criteria.Go to Trials
Image of Sidney & Lois Eskenazi Hospital in Indianapolis, United States.

Composite Intervention for Metabolic Syndrome

18+
All Sexes
Indianapolis, IN
The objective of this study is to pilot a multifaceted, optimized intervention for metabolic syndrome (MetS) in emergency department patients to establish feasibility. Participants (n=20) will be randomized to intervention or control (usual care). The composite intervention will include an educational video outlining the adverse effects of MetS and the benefit of walking, a written exercise prescription with a defined goal of walking 150 minutes per week, a Fitbit accelerometer device, resources for healthy eating practices, periodic text message reminders, and an urgent referral to primary care and our health system's Healthy Me clinic for follow-up visit. Investigators hypothesize that this approach will change patient understanding and motivation to increase physical activity and healthy eating habits.
Recruiting
Has No Placebo
Sidney & Lois Eskenazi Hospital
Image of Duke University Medical Center in Durham, United States.

Cardiometabolic Prevention Clinic for Cardiovascular Disease

18+
All Sexes
Durham, NC
This project is studying whether a team-based specialty clinic can help people with type 2 diabetes and heart disease better manage their blood pressure and cholesterol. The clinic includes coordinated care from heart doctors, kidney doctors, diabetes specialists, and liver doctors. The study will compare two groups of patients: one receiving usual care from their primary care provider, and one referred to the Duke Cardiometabolic Prevention Clinic for multidisciplinary care. The main goals are to find out if this clinic improves blood pressure and cholesterol control over 12 months, increases use of recommended heart medications, and reduces hospital visits and other healthcare use. Participants will be randomly assigned to one of the two groups. Those referred to the clinic will: 1) Meet with a cardiologist for an initial evaluation. 2) Be referred to other specialists (such as endocrinology, nephrology, or hepatology) based on their needs. 3) Receive ongoing, coordinated care from a team of specialists working together to improve their heart and metabolic health.
Recruiting
Has No Placebo
Duke University Medical CenterNeha J Pagidipati, MD, MPH
Have you considered Ionamin clinical trials? We made a collection of clinical trials featuring Ionamin, we think they might fit your search criteria.Go to Trials
Image of Pennington Biomedical Research Center in Baton Rouge, United States.

Continuous Glucose Monitoring for Diabetes

20 - 60
All Sexes
Baton Rouge, LA
Diabetes represents a significant global health burden, with its prevalence continuously rising and causing extensive impacts on individuals, healthcare systems, and society. The International Diabetes Federation (IDF) Diabetes Atlas 2021 reported a global prevalence of 10.5%, with type 2 diabetes (T2D) comprising approximately 90% of cases. In the US, diabetes prevalence stands at 11.6%, affecting roughly 38.4 million adults, with approximately 1.2 million new diagnoses each year. Obesity, affecting over 42% of US adults-including 9.4% with severe obesity-is recognized as the primary risk factor for diabetes. Severe obesity, present in around 30% of T2D patients, markedly elevates the risk for cardiovascular disease, non-alcoholic fatty liver disease, and other comorbidities, resulting in increased mortality rates. Addressing this burden requires coordinated strategies targeting prevention, early diagnosis, effective treatment, and patient education. However, conventional management methods, such as lifestyle modifications and pharmacotherapy, often result in transient weight loss and temporary diabetes remission, with frequent relapses. In contrast, metabolic surgery, notably Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG), has emerged as a highly effective intervention for significant weight loss and durable diabetes remission, particularly among patients with severe obesity and T2D. These procedures improve metabolic outcomes beyond weight reduction, enhancing insulin sensitivity and glycemic control. Consequently, integrating metabolic surgery into standard diabetes care guidelines and expanding patient access is crucial. Although metabolic surgery outperforms intensive medical therapy, traditional assessment methods, such as HbA1c, have notable limitations. HbA1c measures average glucose levels without capturing short-term fluctuations, glucose variability, or hypoglycemia, limiting its utility post-surgery. Continuous glucose monitoring (CGM) offers real-time, detailed insights into glucose patterns, variability, postprandial excursions, and hypoglycemia, making it highly suitable for postoperative monitoring. CGM provides a clearer picture of immediate and long-term metabolic changes following surgery, allowing early identification of abnormal glycemic patterns influenced by surgical alterations in gastrointestinal anatomy and diet. It enables the detection of post-bariatric hypoglycemia (PBH), a recognized complication following metabolic surgery, and improves understanding of hypoglycemia unawareness-critical for enhancing patient safety and clinical outcomes. However, current research on CGM in metabolic surgery remains limited, primarily consisting of cross-sectional or retrospective studies with small sample sizes, lacking preoperative data, and employing short monitoring periods. Therefore, robust studies such as randomized controlled trials (RCTs) are essential to validate CGM's efficacy and inform its broader adoption in clinical practice.
Waitlist Available
Has No Placebo
Pennington Biomedical Research Center
Image of UNC Lineberger Comprehensive Cancer Center in Chapel Hill, United States.

Support Program for Caregivers of Patients with Cancer and Diabetes

18 - 99
All Sexes
Chapel Hill, NC
This study investigates the feasibility, acceptability, and preliminary efficacy of enCompass Humana, a social support intervention for caregivers of patients with cancer and diabetes. The enCompass program aims to improve support for these caregivers through a randomized feasibility study of a pilot-tested coaching and navigation program. Caregiver services and system-level support are essential, but successful interventions for cancer caregivers are rarely standardized or systematically disseminated. Consequently, many programs do not reach the most underserved caregivers. Challenges to implementation include substantial clinical staff involvement, lack of dissemination and implementation information, and failure to tailor interventions to rural contexts. Despite the lack of standardized supportive interventions, national reports and legislative efforts increasingly recognize the need to support caregivers. Caregivers reported unmet needs in all domains of social support, including instrumental help (e.g., in-home help, housekeeping), logistical and coordination support (e.g., food delivery, accompanying patients to appointments), information about illness and progression, emotional support, self-care guidance, and financial assistance (e.g., parking costs, lost wages). Caregivers show high interest in services but cited uncertainty and lack of strategies for accessing resources. Many are unaware of existing services. Interviews with oncology clinicians and healthcare administrators revealed similar findings: resources exist, but there is no system to match them with caregivers' needs. Preliminary data suggest the intervention improves caregiver coping self-efficacy and reduces anxiety and depression in patients. With input from stakeholders, including caregivers, patients, family caregiving experts, and clinical care experts, the study team adapted the CARING application into enCompass to mitigate structural barriers and normalize support-seeking. The long-term goal is to adapt this psychosocial support program to increase self-efficacy, support-seeking, and reduce loneliness among caregivers. It is hypothesized that enCompass will build self-efficacy and coping skills, serving caregivers throughout the patient's illness and complications.
Recruiting
Has No Placebo
UNC Lineberger Comprehensive Cancer Center (+2 Sites)Erin E Kent, PhD
Have you considered Ionamin clinical trials? We made a collection of clinical trials featuring Ionamin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security